Docusign
DOCU
$47.89
-5.62%
DocuSign provides a cloud-based Agreement Cloud platform that enables users to automate agreement processes and execute legally binding e-signatures from virtually any device. As a pioneer and market leader in the e-signature and contract lifecycle management space, the company has established a dominant position with a vast installed base across industries. The current investor narrative centers on DocuSign's transition from a high-growth disruptor to a mature cash-generating business, with debates around its ability to sustain revenue growth amid macroeconomic headwinds and competitive pressures, while its strong free cash flow and profitability improvements have drawn attention from value-oriented investors.…
DOCU
Docusign
$47.89
Related headlines
Investment Opinion: Should I buy DOCU Today?
Rating: Hold. DocuSign is a mature growth company with strong cash flows but decelerating revenue. The consensus 'hold' rating and average target of $59.33 (12.5% upside) support a neutral stance. The thesis is that the stock is fairly valued given the growth slowdown, but the cheap forward P/E provides a margin of safety.
Supporting Evidence: The forward P/E of 10.3x is well below the industry average of 22.0x, implying the market expects significant EPS growth. Revenue growth of 8.7% YoY, while decelerating, still shows positive momentum. The operating margin improved to 13.4% from 7.9% a year ago, and free cash flow margin is a robust 34.9%. The company has no dividend but aggressively repurchases shares ($317.5 million in Q1).
Risks & Conditions: The biggest risks are further revenue deceleration and failure to meet elevated EPS expectations. This Hold would upgrade to Buy if revenue growth stabilizes above 10% or the forward P/E compresses below 8x. It would downgrade to Sell if growth falls below 5% or margins contract. Overall, DocuSign appears fairly valued relative to its history and peers, balancing its strong cash flows against growth concerns.
Sign up to view all
DOCU 12-Month Price Forecast
DocuSign is at an inflection point where its strong cash flows and improving margins are offset by slowing growth. The forward P/E of 10.3x suggests the market is pricing in a pessimistic growth outlook, but the trailing P/E of 34.6x indicates current earnings are expensive. The neutral stance reflects the balanced risk/reward: the stock could re-rate higher if growth stabilizes, but further deceleration would justify the low multiple. Key catalysts to watch are the next earnings report and any guidance changes. An upgrade to bullish would require evidence of re-acceleration, while a downgrade to bearish would follow a growth miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Docusign's 12-month outlook, with a consensus price target around $59.33 and implied upside of +23.9% versus the current price.
Average Target
$59.33
0 analysts
Implied Upside
+23.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$47 - $90
Analyst target range
DocuSign is covered by 18 analysts, with a consensus recommendation of 'hold' (mean rating 2.73 on a 1-5 scale where 1 is strong buy). The average price target is $59.33, implying approximately 12.5% upside from the current price of $52.74. The distribution shows a neutral bias, with several firms maintaining 'hold' or 'neutral' ratings, while a few like BTIG remain bullish with a 'buy'. Recent ratings actions include Citigroup downgrading from 'Buy' to 'Neutral' in April 2026, reflecting tempered expectations. The target price range spans from $46.89 (low) to $90.00 (high), representing a wide 92% spread between the low and high estimates. The high target of $90.00 implies 70.6% upside and likely assumes a successful acceleration in growth or multiple expansion, while the low target of $46.89 suggests 11.1% downside, factoring in continued deceleration or margin compression. This wide dispersion indicates significant uncertainty about DocuSign's future trajectory, with analysts divided on whether the company can reignite growth or will continue to mature. The recent downgrades and price target cuts following Q1 earnings suggest that near-term sentiment remains cautious, but the overall consensus still sees modest upside.
Bulls vs Bears: DOCU Investment Factors
DocuSign presents a classic value vs. growth debate. On the bull side, the company generates robust free cash flow, has improving margins, and trades at a compelling forward P/E of 10.3x, suggesting undervaluation if earnings materialize. The bear case centers on decelerating revenue growth, a trailing P/E premium to peers, and analyst caution. The single most important tension is whether DocuSign can stabilize or re-accelerate revenue growth; if it does, the stock could re-rate higher, but continued deceleration would justify the low forward multiple. Currently, the evidence slightly favors the bear case given the growth trajectory, but the strong cash flows and cheap forward valuation provide a floor. The stock is best suited for patient value investors willing to accept near-term uncertainty.
Bullish
- Strong Free Cash Flow Generation: DocuSign generated $289.4 million in free cash flow in Q1 FY2027, representing a 34.9% FCF margin. Trailing twelve-month FCF reached $1.12 billion, providing ample capital for share repurchases and investment.
- Improving Profitability and Margins: Operating margin expanded to 13.4% in Q1 FY2027 from 7.9% a year ago, driven by operating leverage. Net income grew to $78.2 million, with net margin stable at 9.4%, demonstrating consistent profitability.
- Attractive Forward Valuation: The forward P/E of 10.3x is at a 53% discount to the software industry average of 22.0x, implying significant earnings growth is expected. If DocuSign delivers on EPS estimates, the stock appears undervalued.
- Solid Balance Sheet and Capital Returns: With a debt-to-equity ratio of 0.10 and $565.7 million in cash, DocuSign has a strong balance sheet. The company repurchased $317.5 million in shares in Q1, signaling management confidence.
Bearish
- Decelerating Revenue Growth: Revenue growth slowed to 8.7% YoY in Q1 FY2027 from 9.5% in the prior quarter and 13.5% a year ago. This multi-quarter deceleration suggests market saturation and macro headwinds.
- Elevated Trailing P/E Premium: The trailing P/E of 34.6x is 57% above the software industry average of 22.0x, indicating the stock is expensive on current earnings. Any earnings miss could trigger multiple compression.
- Analyst Skepticism and Downgrades: The consensus rating is 'hold' with a mean rating of 2.73. Citigroup downgraded from 'Buy' to 'Neutral' in April 2026, reflecting tempered expectations. The average target of $59.33 implies only 12.5% upside.
- Sustained Downtrend and Underperformance: The stock is down 32.1% over the past year versus the S&P 500's gain of 18.4%. It trades at 28.6% of its 52-week range, indicating persistent negative sentiment and potential value trap risk.
DOCU Technical Analysis
DocuSign is in a sustained downtrend, with the stock down 32.1% over the past year compared to the S&P 500's gain of 18.4%. The current price of $52.74 sits at 28.6% of its 52-week range ($40.16–$86.65), indicating it is trading near the lower end of its range. This positioning suggests the market has priced in significant pessimism, but also raises the risk of a value trap if fundamentals continue to deteriorate. The stock's beta of 0.90 implies slightly lower volatility than the market, which may offer some downside protection but also limits upside participation in rallies. Short-term momentum shows a sharp recovery, with the stock up 23.9% over the past month and 15.3% over the past three months, contrasting sharply with the one-year decline. This divergence could signal a potential trend reversal or a bear market rally, especially given the stock's 50.9% maximum drawdown over the period. The recent price surge from the June low of $42.46 to $52.74 suggests strong buying interest, but the sustainability of this move is questionable without a catalyst. The 52-week low of $40.16 provides key support, while the 52-week high of $86.65 represents major resistance. A breakout above $86.65 would signal a reversal of the long-term downtrend, while a breakdown below $40.16 could open the door to further declines. The stock's beta of 0.90 indicates it is less volatile than the market, which may appeal to risk-averse investors but also means it may lag during broad market rallies.
Beta
0.90
0.90x market volatility
Max Drawdown
-50.9%
Largest decline past year
52-Week Range
$40-$87
Price range past year
Annual Return
-41.2%
Cumulative gain past year
| Period | DOCU Return | S&P 500 |
|---|---|---|
| 1m | +12.1% | +0.4% |
| 3m | +6.4% | +5.5% |
| 6m | -16.7% | +8.4% |
| 1y | -41.2% | +18.9% |
| ytd | -26.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCU Fundamental Analysis
DocuSign's revenue growth has decelerated significantly, with the most recent quarter (Q1 FY2027) showing revenue of $830.2 million, up 8.7% year-over-year, compared to 9.5% growth in the prior quarter. The multi-quarter trend shows a clear slowdown from 13.5% growth in Q2 FY2026 to 8.7% currently, driven by maturing subscription revenue ($811.2 million, 97.7% of total) and a decline in professional services. The deceleration reflects market saturation and macroeconomic headwinds, but the company's ability to maintain positive growth in a challenging environment is a positive sign. Profitability has improved markedly, with net income of $78.2 million in Q1 FY2027, up from $72.1 million in the prior year quarter, and net margin expanding to 9.4% from 9.4% (stable). Gross margin remains strong at 79.4%, while operating margin improved to 13.4% from 7.9% a year ago, driven by operating leverage. The company is consistently profitable, with trailing twelve-month net income of $315.2 million, and has demonstrated margin expansion through cost discipline. DocuSign's balance sheet is solid, with a debt-to-equity ratio of just 0.10 and $565.7 million in cash. Free cash flow generation is robust at $289.4 million in Q1 FY2027, representing a 34.9% FCF margin, and trailing twelve-month FCF of $1.12 billion. The company has been aggressively repurchasing shares ($317.5 million in Q1), signaling management's confidence in intrinsic value. ROE stands at 16.1%, reflecting efficient capital allocation, while the current ratio of 0.73 indicates adequate liquidity despite a slight current liability overhang.
Quarterly Revenue
$830235000.0B
2026-04
Revenue YoY Growth
+8.7%
YoY Comparison
Gross Margin
79.4%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCU Overvalued?
Since DocuSign is profitable with net income of $78.2 million in the most recent quarter, the P/E ratio is the primary valuation metric. The trailing P/E of 34.6x is elevated, but the forward P/E of 10.3x implies a dramatic earnings acceleration, reflecting analyst expectations of significant EPS growth. This wide gap suggests the market is pricing in a sharp improvement in profitability, which may be optimistic given the revenue deceleration. Compared to the software application industry average P/E of 22.0x, DocuSign's trailing P/E of 34.6x represents a 57% premium. However, the forward P/E of 10.3x is at a 53% discount to the industry forward average of 22.0x, indicating that the market expects DocuSign's earnings to grow rapidly relative to peers. This premium/discount dynamic highlights the binary nature of the stock: if earnings materialize as expected, the stock is cheap; if not, it remains expensive. Historically, DocuSign's trailing P/E has ranged from 3.2x (in Q2 FY2025 due to a one-time tax benefit) to over 2,800x (in Q1 FY2024). The current trailing P/E of 34.6x is near the lower end of its historical range, suggesting that much of the growth optimism has been stripped out. The forward P/E of 10.3x is near historical lows, implying that the market is pricing in a high degree of skepticism about future growth, which could present a value opportunity if the company executes.
PE
34.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~117x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: DocuSign's revenue growth deceleration from 13.5% to 8.7% YoY over the past year is the primary financial risk. If this trend continues, the company may struggle to justify its current valuation. The net margin of 9.4% is modest, leaving limited room for error if costs rise. However, the debt-to-equity ratio of 0.10 and $565.7 million in cash provide a strong liquidity buffer, and free cash flow of $1.12 billion TTM offers cushion against operational setbacks.
Market & Competitive Risks: The stock's trailing P/E of 34.6x is a 57% premium to the software industry average, making it vulnerable to multiple compression if growth disappoints. With a beta of 0.90, DocuSign is slightly less volatile than the market but still sensitive to macro shifts. Competitive threats from Adobe Sign and other e-signature providers could pressure market share. Recent news of analyst downgrades and price target cuts following Q1 earnings highlights near-term sentiment risk.
Worst-Case Scenario: If revenue growth continues to decelerate below 5% and margins compress, the stock could fall to its 52-week low of $40.16, representing a 23.9% decline from the current price of $52.74. In a severe recession, the stock could test lower levels, potentially revisiting the $35 area based on historical drawdowns. The maximum drawdown of 50.9% from the 52-week high suggests that in a worst-case scenario, an investor could lose approximately 24% to the 52-week low, or more if fundamentals deteriorate further.
FAQ
The primary risk is further revenue deceleration, which could compress the already elevated trailing P/E. If growth falls below 5%, the stock could test its 52-week low of $40.16, a 23.9% downside. Competitive pressure from Adobe Sign and other players could erode market share. Macroeconomic headwinds, such as rising interest rates or a recession, could reduce enterprise IT spending, impacting subscription growth. Additionally, the stock's beta of 0.90 offers limited downside protection in a market downturn. The most severe risk is a combination of growth deceleration and margin compression, leading to a re-rating lower.
The 12-month outlook is balanced across three scenarios. The base case (50% probability) sees revenue growth stabilizing around 8-9%, with the stock trading near the average analyst target of $59.33 (12.5% upside). The bull case (25% probability) assumes re-acceleration to 10%+ growth, pushing the stock to $65-$90 (23-71% upside). The bear case (25% probability) envisions growth decelerating below 5%, driving the stock to $40-$50 (24-5% downside). The most likely scenario is the base case, assuming DocuSign maintains its current trajectory without major surprises.
DocuSign's valuation presents a dichotomy. On a trailing basis, the P/E of 34.6x is 57% above the software industry average of 22.0x, suggesting overvaluation relative to current earnings. However, the forward P/E of 10.3x is at a 53% discount to the industry, implying the market expects significant earnings growth. This wide gap indicates that the stock is priced for a sharp improvement in profitability. Historically, the current forward P/E is near the low end of its range, suggesting that much of the growth optimism has been stripped out. Overall, the stock appears undervalued if earnings estimates are met, but overvalued if growth disappoints.
DocuSign offers a mixed risk/reward profile. On the positive side, the forward P/E of 10.3x is well below the software industry average of 22.0x, and the company generates strong free cash flow ($1.12 billion TTM) with a 34.9% margin. The average analyst target of $59.33 implies 12.5% upside. However, revenue growth is decelerating (8.7% YoY) and the trailing P/E of 34.6x is expensive. The stock is a good buy for patient value investors who believe the growth slowdown is temporary and that earnings will materialize. For growth-oriented investors, the deceleration and analyst downgrades suggest waiting for a clearer catalyst.
DocuSign is better suited for long-term investment given its mature growth profile and strong cash flows. The stock's beta of 0.90 indicates lower volatility than the market, making it less attractive for short-term trading. The company does not pay a dividend, so returns depend on capital appreciation. With a forward P/E of 10.3x and robust free cash flow, patient investors could benefit from earnings growth over a 3-5 year horizon. Short-term traders may find the stock range-bound given the lack of near-term catalysts. A minimum holding period of 2-3 years is recommended to allow the growth story to play out.